NCT03690115View on ClinicalTrials.gov

Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

December 5, 2023

Study Completion Date

December 31, 2024

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

Ponatinib 30 MG

Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient

Trial Locations (14)

Unknown

CHU Angers, Angers

CHu Brest, Brest

CHU Caen, Caen

CHU Clermont Ferrand, Clermont-Ferrand

CHU Grenoble, Grenoble

CHU Lille, Lille

CHU Limoges, Limoges

Chevallier, Nantes

Hopital St Antoine, Paris

Hopital St Louis, Paris

CHu Lyon, Pierre-Bénite

CHU Poitiers, Poitiers

CRLC Toulouse, Toulouse

CHU Nancy, Vandœuvre-lès-Nancy

All Listed Sponsors

lead

Versailles Hospital

OTHER

NCT03690115 - Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients | Biotech Hunter | Biotech Hunter